Antigenics Announces Addition of Three New Board Members and Appointment Of CFO.Business Editors/Health/Medical Writers BIOWIRE2K NEW YORK--(BUSINESS WIRE)--March 11, 2003 Antigenics Inc. (Nasdaq:AGEN) announced today that three new members, Margaret Eisen, Wadih Jordan and Mark Kessel, have been appointed to Antigenics' board of directors, effective immediately. The company also announced the appointment of Jeff D. Clark, formerly senior director of corporate finance and development, to the newly created position of chief financial officer. Mr. Clark will continue to be based in Antigenics' corporate office in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of and all of the company's financial functions will report to him. "The collective management, financial and legal proficiency of the three new board members adds comprehensive depth to our board of directors, which will serve us well as we continue to advance through this pivotal stage of development," said Garo H. Armen Garo H. Armen is chairman and chief executive officer of Antigenics Inc., the biotechnology company he cofounded with Pramod Srivastava in 1994. From mid-2002 through 2004, he was chairman of the board of directors for the biopharmaceutical company Elan Corporation plc. Dr. , PhD, chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Antigenics. "Also critical for the company is to have excellent financial leadership in place to ensure that we are optimally positioned to achieve our development goals, and that our corporate governance Corporate Governance The relationship between all the stakeholders in a company. This includes the shareholders, directors, and management of a company, as defined by the corporate charter, bylaws, formal policy, and rule of law. policies are administered properly. Jeff's impressive history with the company, strong background in financial and accounting operations, and his experience in corporate development make him the ideal choice to oversee all of our financial operations as we prepare for commercialization." Continuing Expansion of Leadership Margaret Eisen has more than 20 years of experience in the financial sector and is currently managing director of DeGuardiola Advisors, an investment bank specializing in mergers and acquisitions of investment management firms. Prior to DeGuardiola, she was managing director of North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. Equities of General Motors Investment Management Corporation. Ms. Eisen received a bachelor's degree in government from Smith College, a master's in education from Lesley College, and a master's of business administration from Babson College. Wadih (Bill) Jordan has served as president of NearEast Pharma since 1996, before which he spent 20 years at Cyanamid cy·an·am·ide also cy·an·am·id n. 1. A caustic acidic crystalline compound, NHCNH, prepared by treating calcium cyanamide with sulfuric acid. 2. Calcium cyanamide. Noun 1. International. At Cyanamid, Mr. Jordan advanced from managing director to vice president, and served as chairman of the US Pharmaceuticals Manufacturers Association, Middle East Group. He received a bachelor's degree in agriculture at the American University of Beirut American University of Beirut, at Beirut, Lebanon; English language; chartered by New York State in 1866 as Syrian Protestant College, rechartered 1920 as the American Univ. of Beirut. , Lebanon, and a certificate in international business from Columbia University. Mark Kessel is currently managing director of Symphony Capital, a merchant banking firm specializing in life science and health care companies that he cofounded in 2002. Formerly the managing partner and head of the corporate finance group at the leading international law firm Shearman & Sterling, Mr. Kessel is widely recognized as the inventor of structured financial products for the pharmaceutical and biotechnology industries. He received a bachelor's degree in economics from the City College of New York “City College” redirects here. For other uses, see City College (disambiguation). CCNY was the first free public institution of higher education in the United States[3] and a law degree from Syracuse University. Jeff Clark's professional experience includes several years at PricewaterhouseCoopers, where he worked in the firm's tax mergers and acquisitions consulting practice, where he advised clients on structuring and due diligence matters for numerous corporate transactions. Prior to joining Antigenics in 2001, he was vice president of finance and controller for PrimeStreet Corporation, an Internet firm specializing in small business financing, where he built and led the finance and accounting function and was a key member of the firm's senior management team. Mr. Clark, a certified public accountant Certified Public Accountant (CPA) An accountant who has met certain standards, including experience, age, and licensing, and passed exams in a particular state. , began his career at Coopers & Lybrand LLP LLP - Lower Layer Protocol , and earned his bachelor's and master's degrees from the University of Texas School of Business in Austin, Texas. About Antigenics Antigenics is developing personalized immunotherapeutics and revolutionary treatments for cancers, infectious diseases and autoimmune disorders. The company's lead product is Oncophage, a late-stage, personalized cancer vaccine being evaluated in several indications, including kidney cancer and metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. melanoma. Antigenics' portfolio also includes AG-858, a personalized cancer vaccine entering Phase II development; Aroplatin and ATRA-IV, two Phase II liposomal chemotherapeutics; and AG-702/X, a Phase I genital herpes immunotherapeutic. For more information about Antigenics, please visit www.antigenics.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion